TOP 10 COMPANIES IN CANCER IMMUNOTHERAPY MARKET

Immunotherapy is one of the most recent approaches for cancer therapy. It is a treatment that uses body’s own immune system to help fight cancer. It is widely used in hospital settings and clinics for the treatment of different types of cancers such as lung cancer, breast cancer, colorectal cancer, multiple myeloma, melanoma, prostate cancer, and other types of cancer.

The global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to 2024 to reach USD 152.83 billion by 2024.

Here are the top 10 companies operating in cancer immunotherapy market

1. AstraZeneca

Founded in 1992 and headquartered at London, UK, AstraZeneca is a global biopharmaceutical company that focuses on discovery and development of products followed by manufacturing and selling in the market. The Company operates through four major divisions namely Oncology, Cardiovascular & Metabolic Disease (CVMD), Respiratory, and Others including selectively pursuing therapies in Autoimmunity, Infection, and Neuroscience. The cancer immunotherapy products are provided under oncology division.

The Group operates in over 100 countries and the size of operations within each territory varies. The company sells its products across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Some of the major subsidiaries of the company are AstraZeneca S.A. / N.V. (Belgium), AstraZeneca Canada Inc., AstraZeneca Pharmaceuticals Co., Limited (China), AstraZeneca A/S (Denmark), AstraZeneca Holding GmbH (Germany), AstraZeneca Holding GmbH (India), and Amylin Pharmaceuticals, LLC (US)

2. Amgen

amgenFounded in 1986 and headquartered at California, U.S., Amgen discover, develop, manufacture and deliver human therapeutics in the market. The Company operates in the human therapeutics segment. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec), and Corlanor (ivabradine).

The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. The company has its presence in more than 100 countries. Some of the major subsidiaries of the company are Amgen (Europe) GmbH, Amgen Fremont Inc. (U.S.), Amgen Technology (Ireland), and BioVex, Inc. (U.S.).

3. Bristol-Myers Squibb

Founded in 1887 and headquartered at New York, U.S., Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. The Company operates through two major divisions, namely, Prioritized Brands and Established Brands. The cancer immunotherapy products such as Opdivo and Yervoy are provided by prioritized brands segment.

The Company focuses on the research and development department to develop new drug and therapy. This is evident from the rise in R&D expenditure of the company. R&D expenditure increased from $4.94 billion in 2016 to $6.41 billion in 2017. Some of the major subsidiaries of the company are BMS Benelux Holdings B.V., (Netherlands), BMS Holdings Spain S.L., BMS Pharmaceutical Korea Limited, Bristol-Myers Squibb (China) Investment Co., Ltd., Bristol-Myers Squibb EMEA (France), and Bristol-Myers Squibb MEA GmbH (Germany).

A report into the projected growth of the current Cancer Immunotherapy Market by Meticulous Research® has produced some incredible forecasts for the industry. By 2022, it’s expected to have grown at a CAGR of 13.8%, reaching over $152.83 billion.

4. Eli Lilly

Founded in 1876 and headquartered at Indiana, U.S., Eli Lilly is engaged in drug manufacturing business. The Company discovers, develops, manufactures, and markets products in two segments: human pharmaceutical products and animal health products. The reporting segments of the company include Endocrinology, Oncology, Cardiovascular, Neurosciences, Immunology, Other Human Pharmaceuticals, and Animal Health Products. The cancer immunotherapy products are provided by Oncology division of the company.

Eli Lilly and Company (US), Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (Taiwan), Inc., Eli Lilly and Company Limited (UK), Eli Lilly do Brasil Limitada, Eli Lilly Finance, S.A., Lilly Deutschland GmbH (Germany), and Lilly France S.A.S. are some of the major subsidiaries of the company.

5. Johnson and Johnson

johnson and johnsonFounded in 1953 and headquartered at Belgium, Janssen Pharmaceutical is a fully owned subsidiary of Johnson and Johnson (US). Johnson and Johnson manufacture, market, and sale the consumer healthcare products, medical devices, and pharmaceuticals. The company operates in three major division namely, pharmaceutical division, medical devices division, and consumer division. The Pharmaceuticals segment operates in six primary therapeutic areas: immunology, infectious diseases, oncology, neuroscience, pulmonary hypertension, and cardiovascular and metabolic diseases. The segment’s operating companies include Janssen Biotech and Janssen Pharmaceuticals.

Some of the major subsidiaries of the company are Janssen Oncology, Inc. (US), Janssen Pharmaceuticals, Inc. (US), Apsis Germany GmbH (Germany), DePuy International Limited (UK), Janssen Biologics (Ireland), Janssen Biologics B.V. (Netherlands), Janssen Holding GmbH (Switzerland), Janssen Pharmaceutical K.K. (Japan), Janssen-Cilag (France), Johnson & Johnson (China) Investment Ltd. (China), and Johnson & Johnson Private Limited (India).

6. Merck & Co.

Founded in 1891 and headquartered at New York, U.S., Merck & Co. is a global healthcare company. The company offers health solutions through two main divisions namely Pharmaceutical Segment Sales and Other Segment Sales. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers, and other institutions.

Schering-Plough Produtos de Oncologia, Unipessoal Lda. (Portugal), Merck Canada Inc., Merck Holdings II Corp. (US), Merck Sharp & Dohme (Asia) Limited (Korea), MSD (Shanghai) Pharmaceuticals Consultancy Co., Ltd. (China), MSD Animal Health Limited (UK), MSD Beteiligungs GmbH & Co KG (Germany), and MSD Laboratories India LLC are some of the major subsidiaries of the company.

7. Novartis

Founded in 1996 and headquartered at Base, Switzerland, Novartis is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s range of products includes innovative pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices. Company operates through three major segments namely, Innovative Medicines, Sandoz, and Alcon. Innovative Medicines researches, develops, manufactures, distributes and sells prescription medicines to develop health outcomes for patients and healthcare providers. The Innovative Medicines is organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. The Novartis Oncology business unit is responsible for the commercialization of products in the therapeutic area of oncology.

Company sells its products in more than 155 countries. AveXis, Inc. (US), Novartis Groupe France S.A., Novartis India Ltd., Chiron Corporation (US), Hexal AG (Germany), Alcon (US), and Snadoz (Germany) are some of the major subsidiaries of the company.

8. Pfizer Inc.

Founded in 1849 and headquartered at New York, U.S., Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The products for cancer therapeutics and immunotherapeutic are provided by the innovative health segment. It mainly focuses on the acquisition of the companies to strengthen the existing product portfolio, which is evident from acquisition of Anacor and Medivation Inc. (US).

The Company is active in sales of its product in more than 180 countries. More than 87 projects are in the clinical research and development and it has 58 manufacturing sites spanning globally. Some of the major subsidiaries of the company are Anacor Pharmaceuticals, Inc. (US), Medivation Field Solutions LLC (US), Pfizer (China) Research and Development Co. Ltd., Pfizer (Perth) Pty Limited, Pfizer AG (Switzerland), Pfizer Canada Inc., Pfizer Deutschland GmbH (Germany), and Pfizer East India B.V. (The Netherlands).

9. F.Hoffmann-La Roche

Founded in 1896 and headquartered at Basel, Switzerland, F. Hoffmann-La Roche is a global research-based pharmaceuticals and diagnostics manufacturer. The Company operates in the market through two main divisions namely, Pharmaceuticals and Diagnostics Division. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. Roche investigates diseases in diverse areas such as oncology, neurodevelopmental and neurodegenerative conditions, ophthalmology, immunology, inflammation and infectious diseases.

The drugs and therapies for cancer are provided under the pharmaceutical division of the company. Roche has about 27 drug and product development in their current pipeline (As of December 2017), of which 21 are in Phase 1, 2 are in Phase 2, and 3 are in Phase 3. Foundation Medicine Inc. (US), Flatiron Health Inc. (US), Ignyta Inc. (US), PVT Probenverteiltechnik GmbH (Germany), Genentech Canada, and Chugai Pharmaceuticals (Japan) are some of the major subsidiaries of the company.

10. Celgene Corporation

Founded in 1986 and headquartered at New Jersey, US, Celgene Corporation is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Commercial stage products include REVLIMID, POMALYST/IMNOVID, OTEZLA, ABRAXANE, VIDAZA, THALOMID (sold as THALOMID), and IDHIFA.

Juno Therapeutic (U.S.), Apoptos, Inc. (U.S.), Celgene Ab (Finland), Celgene Brasil Productos Farmaceuticos Ltda., Celgene BV (Netherlands), Celgene Chemicals Sarl (Switzerland), Celgene Europe, Limited (U.K.), Celgene GmbH (Germany), and Celgene Pharmaceuticals (Shanghai) Co., Ltd are some of the major subsidiaries of the company.

Authoritative Research on the Cancer Immunotherapy Market – Global Opportunity Analysis and Industry Forecast (2018-2024)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

  • Recent financial performance
  • Key products
  • Significant company strategies
  • Partnerships and acquisitions

The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.

Please download report pages and learn more:

Leave a Reply

Your email address will not be published. Required fields are marked *